Literature DB >> 29696294

Ten things ICU specialists need to know about direct oral anticoagulants (DOACs).

Jakob Stensballe1,2, Morten Hylander Møller3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29696294     DOI： 10.1007/s00134-018-5192-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  17 in total

1.  Hypocoagulability, as evaluated by thrombelastography, at admission to the ICU is associated with increased 30-day mortality.

Authors:  Pär I Johansson; Jakob Stensballe; Nis Vindeløv; Anders Perner; Kurt Espersen
Journal:  Blood Coagul Fibrinolysis       Date:  2010-03       Impact factor: 1.276

2.  The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).

Authors:  Sacha Solbeck; Annette Schophuus Jensen; Christian Maschmann; Jakob Stensballe; Sisse Rye Ostrowski; Pär I Johansson
Journal:  Scand J Clin Lab Invest       Date:  2018-01-05       Impact factor: 1.713

Review 3.  Bleeding and coagulopathies in critical care.

Authors:  Beverley J Hunt
Journal:  N Engl J Med       Date:  2014-02-27       Impact factor: 91.245

Review 4.  Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.

Authors:  Jonathan Ac Sterne; Pritesh N Bodalia; Peter A Bryden; Philippa A Davies; Jose A López-López; George N Okoli; Howard Hz Thom; Deborah M Caldwell; Sofia Dias; Diane Eaton; Julian Pt Higgins; Will Hollingworth; Chris Salisbury; Jelena Savović; Reecha Sofat; Annya Stephens-Boal; Nicky J Welton; Aroon D Hingorani
Journal:  Health Technol Assess       Date:  2017-03       Impact factor: 4.014

5.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.

Authors:  Kathrine O F Jensen; Svend H Hansen; Jens P Goetze; Amalie Jesting; Jakob Stensballe; Henrik Hansen
Journal:  Eur J Haematol       Date:  2017-10-06       Impact factor: 2.997

Review 7.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

8.  Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality.

Authors:  Patrick G Lyons; Scott T Micek; Nicholas Hampton; Marin H Kollef
Journal:  Crit Care Med       Date:  2018-05       Impact factor: 7.598

Review 9.  Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.

Authors:  José A López-López; Jonathan A C Sterne; Howard H Z Thom; Julian P T Higgins; Aroon D Hingorani; George N Okoli; Philippa A Davies; Pritesh N Bodalia; Peter A Bryden; Nicky J Welton; William Hollingworth; Deborah M Caldwell; Jelena Savović; Sofia Dias; Chris Salisbury; Diane Eaton; Annya Stephens-Boal; Reecha Sofat
Journal:  BMJ       Date:  2017-11-28

10.  Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

Authors:  Xiaoli Wang; Sabiha Mondal; Jessie Wang; Giridhar Tirucherai; Donglu Zhang; Rebecca A Boyd; Charles Frost
Journal:  Am J Cardiovasc Drugs       Date:  2014-04       Impact factor: 3.571
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.